

## NICE TA implementation guidance – Biologics for ankylosing spondylitis and non-radiographic axial spondyloarthritis

### Recommendation

Detail local guidance supporting the implementation of NICE technology appraisal (TA) 383 and TA 407 on biologics for the treatment of ankylosing spondylitis and non-radiographic axial spondyloarthritis

This guidance has been developed to ensure consistency in provision of treatment across Kent and Medway, using the drug with lowest acquisition cost, taking into account extra-articular manifestations.

The guidance does not specifically address the care of patients with ankylosing spondylitis who do not respond to two TNF-alpha inhibitors and secukinumab, or patients with non-radiographic axial spondyloarthritis who do not respond to two TNF-alpha inhibitors.

**Note:** The Full Guidance Document is available by clicking [here](#).

Please note that the link above goes to the Canterbury & Coastal CCG site – but the same document is available on all four East Kent CCG websites.

**This guidance was approved at the June, 2017 – EKPG.**

**Approved by:** East Kent Prescribing Group (*Representing Ashford CCG, Canterbury and Coastal CCG, South Kent Coast CCG and Thanet CCG*)

**Date:** June 2017

**Address:** c/o Canterbury and Coastal CCG, Ground Floor, Council Offices, Military Road, Canterbury, Kent, CT1 1YW

**Contact:** T: 03000 425019 | E: [accg.eastkentprescribing@nhs.net](mailto:accg.eastkentprescribing@nhs.net)